<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003693.pub2" GROUP_ID="STROKE" ID="529001030610121427" MERGED_FROM="" MODIFIED="2008-10-14 11:56:01 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-10-14 11:56:01 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Thrombolysis for cerebral vein and dural sinus thrombosis</TITLE>
<CONTACT MODIFIED="2008-10-14 11:56:01 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16448" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alfonso</FIRST_NAME><LAST_NAME>Ciccone</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>alfonso.ciccone@ospedaleniguarda.it </EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Azienda Ospedale Niguarda Ca' Granda</ORGANISATION><ADDRESS_1>Piazza Ospedale Maggiore 3</ADDRESS_1><CITY>Milano</CITY><ZIP>20162</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02 64442348</PHONE_1><PHONE_2>+39 02 64442791</PHONE_2><FAX_1>+39 02 64442819</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-14 11:56:01 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16448" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alfonso</FIRST_NAME><LAST_NAME>Ciccone</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>alfonso.ciccone@ospedaleniguarda.it </EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Azienda Ospedale Niguarda Ca' Granda</ORGANISATION><ADDRESS_1>Piazza Ospedale Maggiore 3</ADDRESS_1><CITY>Milano</CITY><ZIP>20162</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02 64442348</PHONE_1><PHONE_2>+39 02 64442791</PHONE_2><FAX_1>+39 02 64442819</FAX_1></ADDRESS></PERSON><PERSON ID="16445" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Patrícia</FIRST_NAME><LAST_NAME>Canhão</LAST_NAME><EMAIL_1>pcanhao@fm.ul.pt</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Santa Maria Hospital</ORGANISATION><ADDRESS_1>Av Prof Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-045</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>351-21-7974956</PHONE_1><FAX_1>351-21-7957474</FAX_1></ADDRESS></PERSON><PERSON ID="16465" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Filipa</FIRST_NAME><LAST_NAME>Falcão</LAST_NAME><EMAIL_1>fnfalcao@esoterica.pt</EMAIL_1><ADDRESS><DEPARTMENT>Serviço de Neurologia</DEPARTMENT><ORGANISATION>Hospital Rainha Santa Isabel</ORGANISATION><ADDRESS_1>Av Xanana Gusmão Apt 45</ADDRESS_1><CITY>Torres Novas</CITY><ZIP>2350-754</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>249810185</PHONE_1><FAX_1>249810186</FAX_1></ADDRESS></PERSON><PERSON ID="16470" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>José</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Ferro</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>jmferro@fm.ul.pt</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Santa Maria Hospital</ORGANISATION><ADDRESS_1>Av Prof Egas Moniz</ADDRESS_1><CITY>Lisboa</CITY><ZIP>1649-045</ZIP><COUNTRY CODE="PT">Portugal</COUNTRY><PHONE_1>351-21-7974956</PHONE_1><FAX_1>351-21-7957474</FAX_1></ADDRESS></PERSON><PERSON ID="11542" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roberto</FIRST_NAME><LAST_NAME>Sterzi</LAST_NAME><POSITION>Direttore Dipartimento di Medicina</POSITION><EMAIL_1>rsterzi@aliceposta.it</EMAIL_1><EMAIL_2>roberto.sterzi@hsacomo.org</EMAIL_2><MOBILE_PHONE>+39 347 1645475</MOBILE_PHONE><ADDRESS><DEPARTMENT>Direttore UO Neurologia</DEPARTMENT><ORGANISATION>Azienda Ospedaliera Sant'Anna</ORGANISATION><ADDRESS_1>Via Napoleona, 50</ADDRESS_1><CITY>Como</CITY><ZIP>22100</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 031 5855347</PHONE_1><FAX_1>+39 031 5855178</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-08 16:02:37 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="4" MONTH="6" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="3" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="8" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-08 15:56:38 +0100" MODIFIED_BY="Hazel Fraser"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-14 10:06:18 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-10-08 15:57:42 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-10-08 15:57:42 +0100" MODIFIED_BY="Hazel Fraser">Thrombolysis for cerebral vein and dural sinus thrombosis</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-08 15:57:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is no good evidence on the effects of thrombolysis for cerebral vein thrombosis. Blood drains from the brain into the cerebral veins and then into the cerebral venous sinuses. If a clot forms in one of these blood vessels, it can cause headaches, seizures, loss of consciousness and other neurological symptoms. Clot dissolving treatments (thrombolytic therapy) could help to clear the clot and improve the patients' condition. However, thrombolytic therapy can cause serious or even fatal bleeding in the brain. The reviewers did not find any reliable evidence from randomised trials about the balance of risk and benefit from this treatment. Randomised controlled trials of this treatment are needed.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Treatment of cerebral sinus thrombosis with thrombolytics has been reported in cases with a deteriorating clinical course despite anticoagulant therapy. The rationale of this treatment is to promote rapid recanalisation of the occluded sinus.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To review the available evidence on the efficacy and safety of thrombolysis in confirmed cerebral sinus thrombosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group trials register (March 2003), the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I>, Issue 1, 2003), MEDLINE (1966 to March 2003), EMBASE (1980 to March 2003), and reference lists of all relevant publications. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We aimed to analyse separately unconfounded randomised controlled trials comparing thrombolytic agent with placebo, or thrombolytic agent with antithrombotic therapy, or thrombolytic agent and antithrombotic with antithrombotic alone, in patients with dural sinus thrombosis (confirmed by MR venography, intra-arterial venography or CT venography).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two groups of reviewers independently applied the inclusion criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No randomised controlled trials were found.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is currently no available evidence from randomised controlled trials regarding the efficacy or safety of thrombolytic therapy in dural sinus thrombosis. A randomised controlled trial is justified to test this therapy especially in patients predicted to have a poor prognosis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-14 10:06:18 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2008-10-14 10:02:05 +0100" MODIFIED_BY="Hazel Fraser">
<P>Cerebral vein and dural sinus thrombosis (CVDST) is an uncommon condition which, over the past decade, has been diagnosed more frequently due to greater awareness and the availability of non-invasive diagnostic techniques. CVDST has a wide spectrum of clinical presentation and outcome. Headache is the presenting symptom in 70% to 100% of cases, while seizures, focal deficits, impairment of consciousness, visual disturbances and papilledema occur in 33% to 75% of cases. It has a generally good prognosis but mortality varies between 5% and 30% in case series (<LINK REF="REF-Bousser-1985" TYPE="REFERENCE">Bousser 1985</LINK>; <LINK REF="REF-Allroggen-2000" TYPE="REFERENCE">Allroggen 2000</LINK>).</P>
<P>Clinical heterogeneity, rarity of the disease, and the few clinical trials available contribute to uncertainty on the best therapeutic approach. Anticoagulant therapy is widely used and many authors consider it the first line therapy (<LINK REF="REF-Bousser-1999" TYPE="REFERENCE">Bousser 1999</LINK>; <LINK REF="REF-Benamer-2000" TYPE="REFERENCE">Benamer 2000</LINK>; <LINK REF="REF-De-Bruijn-2001" TYPE="REFERENCE">De Bruijn 2001</LINK>). The Cochrane review by Stam et al showed that anticoagulants appear to be safe and are associated with an apparent reduction in the risk of death or dependency although not reaching statistical significance (<LINK REF="REF-Stam-2003" TYPE="REFERENCE">Stam 2003</LINK>).</P>
<P>The rationale of anticoagulant therapy is to avoid thrombus extension, to favour spontaneous thrombus dissolution, and to prevent pulmonary embolism. However, despite anticoagulant therapy, some patients deteriorate. In these cases systemic or local thrombolysis via selective catheterisation of the occluded sinuses is considered (<LINK REF="REF-Bousser-1999" TYPE="REFERENCE">Bousser 1999</LINK>; <LINK REF="REF-Benamer-2000" TYPE="REFERENCE">Benamer 2000</LINK>).</P>
<P>The rationale of thrombolytic therapy is to obtain a rapid recanalisation of the vessels affected and therefore stop the clinical deterioration. Some case series report an excellent outcome (<LINK REF="REF-Di-Rocco-1981" TYPE="REFERENCE">Di Rocco 1981</LINK>; <LINK REF="REF-Higashida-1989" TYPE="REFERENCE">Higashida 1989</LINK>; <LINK REF="REF-Persson-1990" TYPE="REFERENCE">Persson 1990</LINK>; <LINK REF="REF-Barnwell-1991" TYPE="REFERENCE">Barnwell 1991</LINK>; <LINK REF="REF-Smith-1994" TYPE="REFERENCE">Smith 1994</LINK>; <LINK REF="REF-Horowitz-1995" TYPE="REFERENCE">Horowitz 1995</LINK>; <LINK REF="REF-Kermode-1995" TYPE="REFERENCE">Kermode 1995</LINK>; <LINK REF="REF-Aoki-1997" TYPE="REFERENCE">Aoki 1997</LINK>; <LINK REF="REF-Holder-1997" TYPE="REFERENCE">Holder 1997</LINK>; <LINK REF="REF-Kim-1997" TYPE="REFERENCE">Kim 1997</LINK>; <LINK REF="REF-Rael-1997" TYPE="REFERENCE">Rael 1997</LINK>; <LINK REF="REF-Renowden-1997" TYPE="REFERENCE">Renowden 1997</LINK>; <LINK REF="REF-Smith-1997" TYPE="REFERENCE">Smith 1997</LINK>; <LINK REF="REF-Frey-1999" TYPE="REFERENCE">Frey 1999</LINK>; <LINK REF="REF-Chow-2000" TYPE="REFERENCE">Chow 2000</LINK>) but the efficacy of general use of thrombolysis in CVDST is unknown. Brain haemorrhage is the most feared complication.</P>
<P>A systematic review of controlled clinical trials appears necessary to evaluate the potential efficacy and safety of thrombolysis in patients with CVDST either alone or after pre-treatment with anticoagulant.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To conduct a systematic review of randomised controlled trials (RCTs) of thrombolysis in CVDST to evaluate whether:<BR/>(1) such treatments are significantly effective in increasing complete recovery;<BR/>(2) they are safe enough for general use.</P>
<P>Prior to starting the review, it seemed unlikely that there would be sufficient evidence to answer these questions reliably, but there might be enough to: <BR/>(1) indicate whether it might be worthwhile doing RCTs; <BR/>(2) guide trial protocols; <BR/>(3) pre-specify the hypotheses to be tested in any future trials.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-14 10:05:54 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-10-14 10:04:05 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>We aimed to consider all apparently unconfounded RCTs of thrombolytic agent(s) in acute CVDST, recognised within 15 days of symptoms onset. The intent was to include quasi-randomised trials as well as strictly randomised trials and whether or not outcome was assessed blind to treatment allocation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients over 18 years of age with definite CVDST, within 15 days of symptoms onset, were to be included. Trials including patients diagnosed by brain computerised tomography (CT) scan alone were not to be included. </P>
<P>We defined CVDST as a symptomatic clinical condition with the demonstration of vein/sinus thrombosis by MR venography, intra-arterial venography or CT venography. </P>
<P>The intent was to exclude cases of involvement of the cortical veins alone, without sinus thrombosis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-14 10:03:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>We aimed to analyse separately the following comparisons:<BR/>(1) thrombolysis versus placebo or open control;<BR/>(2) thrombolysis versus full dose anticoagulation (unfractionated heparin or low-molecular weight heparin followed by oral anticoagulants);<BR/>(3) thrombolysis versus less intense anticoagulant (low-dose heparin, given subcutaneously);<BR/>(4) thrombolysis versus antiplatelet treatment;<BR/>(5) thrombolysis versus 'standard therapy' (i.e. a potentially confounded therapy).</P>
<P>Any clot dissolving (thrombolytic) agents, regardless of duration, dosage and route of administration - either via selective catheterisation of the occluded sinus or by peripheral intravenous injection or combined - were accepted for the treatment group. The intent was to consider, in separate analyses, thrombolysis after pre-treatment or concomitant treatment with anticoagulants or alone and whether or not long-term anticoagulant treatment was used (see 'Methods of the review' section for the analyses foreseen to avoid the possible confounding effect of an interaction between thrombolytic agents and anticoagulants).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-14 10:04:05 +0100" MODIFIED_BY="Hazel Fraser">
<P>(1) The number of patients who recovered completely (modified Rankin Scale 0 or 1) at the end of the scheduled follow up.<BR/>(2) Death from any cause at the end of the follow up.<BR/>(3) The number of patients with symptomatic fatal or non-fatal intracranial haemorrhage (any new intracranial haemorrhage or haemorrhagic transformation of a cerebral infarct that developed after randomisation, that is documented by CT or MR scanning, or at autopsy, and that caused clinically manifest deterioration of the neurological condition);<BR/>(4) The number of patients with any major extracranial haemorrhage (any bleeding that requires transfusion or significant surgical intervention, or that causes permanent disabling deficit; e.g. intra-ocular bleeding causing blindness).</P>
<P>We also aimed to extract any available information about safety in both the thrombolytic and control groups.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-08 16:01:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group trials register, which was last searched by the Review Group Co-ordinator in March 2003. In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, Issue 1, 2003) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (1966 to March 2003) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and EMBASE (1980 to March 2003) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). The reference lists of all relevant studies found were screened to identify further trials.</P>
<P>Titles identified by the searching were inspected by AC. Abstracts of references with titles of interest were examined to determine relevance. When relevance was not clear from the abstract, or when no abstract was available, a copy of the article was obtained.</P>
<P>All the reviewers are involved in the International Study on Cerebral Vein and Dural Sinus Thrombosis (<LINK REF="REF-ISCVT-2003" TYPE="REFERENCE">ISCVT 2003</LINK>), a large multinational observational ongoing study on CVDST. Through this network they are in contact with those interested in CVDST and could potentially plan or participate in a RCT in Europe, Australia, and North, Central and South America.<BR/>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-14 10:05:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two groups of reviewers (the Portuguese group: PC, FF and JMF; and the Italian group: AC and RS) independently selected trials for inclusion in the review from all the potential studies identified. If the trials selected by the two groups of reviewers were different, differences were resolved by discussion among all reviewers.</P>
<P>For each included trial the two groups of reviewers extracted information about the method of randomisation, blinding of outcome evaluators and whether all the randomised patients were accounted for in the analysis. The authors of the trials were to be contacted if the above information was not available in the published reports. This information was to be used to evaluate quality. The five reviewers were to assess the quality of the trials independently. Concealment of randomisation, blinding in outcome evaluation and intention to treat analysis were to be evaluated and graded as present (+), absent (-) or unclear (0). The interobserver agreement in the overall quality score was to be summarised using the weighted kappa statistic.</P>
<P>Complete recovery was selected as first outcome measure, because it is clinically relevant for patients with CVDST who have, in general, a good prognosis.</P>
<P>Concerning the analysis on safety, the intent was to consider only symptomatic intracranial haemorrhages, with clinical deterioration or death, and major extracranial haemorrhages requiring medical interventions or causing permanent deficiency.</P>
<P>To avoid the possible confounding effect of an interaction between thrombolytic agents and anticoagulants, we planned to perform analyses with and without inclusion of trials in which patients allocated to thrombolysis were also treated with anticoagulants. If the difference in the expected risks and benefits of the two modalities of treatment is more than could be attributed to chance, then the results of the two procedures should not be combined. To explore this, we aimed to test for heterogeneity using a standard chi-square test.</P>
<P>A weighted estimate of the treatment effects across trials (odds ratio (OR), absolute risk reduction) was to be calculated using a fixed-effect model. For interpreting the results, 95% confidence intervals (CI) will be used.</P>
<P>The intent was to do subgroup analyses using statistical tests for interaction for the subgroups according to site of thrombosis, age group, presence of deficits, level of consciousness and presence of haemorrhagic lesions previous to the treatment, but only if the overall results were statistically significant.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-14 10:06:18 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION>
<P>No published, ongoing or planned RCTs were identified. We found only one study of local urokinase versus systemic heparin for superior sagittal sinus thrombosis (<LINK REF="STD-Wasay-2001" TYPE="STUDY">Wasay 2001</LINK>) but this was excluded from the analysis because it was non-randomised and retrospective. <BR/>
</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No studies were available for inclusion in a meta-analysis.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-14 10:06:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>The results of the electronic searches were as follows.</P>
<P>Only additional articles found are counted (for example: the EMBASE search yielded 1091 articles not found in MEDLINE).</P>
<P>MEDLINE: 661 references<BR/>EMBASE: 1091 references<BR/>Cochrane Central Register of Controlled Trials: 14<BR/>Cochrane Stroke Group trials register: 0</P>
<P>No RCTs were found.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>We searched extensively for RCTs but found none. </P>
<P>Three of the authors (PC, FF and JMF) recently published a systematic review of cases with CVDST treated with thrombolytics (<LINK REF="REF-Canh_x00e3_o-2003" TYPE="REFERENCE">Canhão 2003</LINK>). Seventy-two publications (169 patients), found through a search from 1966 to July 2001, were analysed; thrombolytic therapy appeared to be reasonably safe but its efficacy could not be assessed as no RCTs were identified. Since then at least 15 further reports of more than 40 cases with CVDST treated with thrombolytics have been published (<LINK REF="REF-Del-Rio-2001" TYPE="REFERENCE">Del Rio 2001</LINK>; <LINK REF="REF-Ra-2001" TYPE="REFERENCE">Ra 2001</LINK>; <LINK REF="STD-Wasay-2001" TYPE="STUDY">Wasay 2001</LINK>; <LINK REF="REF-Chaves-2002" TYPE="REFERENCE">Chaves 2002</LINK>; <LINK REF="REF-De-Asis-2002" TYPE="REFERENCE">De Asis 2002</LINK>; <LINK REF="REF-Funabiki-2002" TYPE="REFERENCE">Funabiki 2002</LINK>; <LINK REF="REF-Huh-2002" TYPE="REFERENCE">Huh 2002</LINK>; <LINK REF="REF-Kao-2002" TYPE="REFERENCE">Kao 2002</LINK>; <LINK REF="REF-Ming-2002" TYPE="REFERENCE">Ming 2002</LINK>; <LINK REF="REF-Perez_x002d_Duenas-2002" TYPE="REFERENCE">Perez-Duenas 2002</LINK>; <LINK REF="REF-Strzyzewska-2002" TYPE="REFERENCE">Strzyzewska 2002</LINK>; <LINK REF="REF-Tarani-2002" TYPE="REFERENCE">Tarani 2002</LINK>; <LINK REF="REF-Yang-2002" TYPE="REFERENCE">Yang 2002</LINK>; <LINK REF="REF-Soleau-2003" TYPE="REFERENCE">Soleau 2003</LINK>). These articles indicate that the use of thrombolysis for CVDST is growing and, in some centres, thrombolysis is even an alternative to anticoagulant therapy in the acute phase (<LINK REF="STD-Wasay-2001" TYPE="STUDY">Wasay 2001</LINK>). A RCT on thrombolytic therapy for CVDST is, therefore, ethically justifiable and urgently needed: it is more appropriate to include patients in a RCT than treating them with a therapy whose risks and benefits are still unknown. </P>
<P>One of the issues in designing a RCT would be how to treat the control group. A placebo-controlled study might not be approved, as in many countries anticoagulation is considered an acceptable routine treatment for CVDST, and the Cochrane review by Stam et al also suggested that anticoagulants might be beneficial (<LINK REF="REF-Stam-2003" TYPE="REFERENCE">Stam 2003</LINK>). Thrombolysis versus anticoagulants could be a more appropriate comparison even if it might show that thrombolysis is better than anticoagulation but not whether it is better than placebo or no treatment. On the other hand, the comparison of thrombolysis plus anticoagulant versus anticoagulant alone could be confounded by the interaction of anticoagulants and thrombolytics, which would make the interpretation of the study results difficult. Since in most cases the course is benign, some workers advocate thrombolysis only for those who deteriorate despite anticoagulants and indicate anticoagulants as a safer treatment for the others (<LINK REF="REF-Bousser-1999" TYPE="REFERENCE">Bousser 1999</LINK>; <LINK REF="REF-Benamer-2000" TYPE="REFERENCE">Benamer 2000</LINK>) but there are no data to argue that anticoagulation is safer than thrombolysis for CVDST or vice versa. A pragmatic RCT allowing randomisation of patients in all cases of therapeutic uncertainty, for instance those cases identified at high risk of poor prognosis in large cohorts of CVDST patients (<LINK REF="REF-Crassard-2003" TYPE="REFERENCE">Crassard 2003</LINK>; <LINK REF="REF-Ferro-2003" TYPE="REFERENCE">Ferro 2003</LINK>), would be probably the best solution to this issue. Another important point would be whether to test local or systemic thrombolysis. Also in this case there are no data to indicate which route of administration is better; although the systemic route is more feasible, available and less invasive, the literature is dominated by cases treated with local thrombolysis (<LINK REF="REF-Canh_x00e3_o-2003" TYPE="REFERENCE">Canhão 2003</LINK>). As there is greater experience of the local route of administration, this one may be selected for being tested in a RCT. <BR/> </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The available evidence does not support the routine use of thrombolysis for patients with cerebral vein and dural sinus thrombosis.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The question of whether thrombolysis does more good than harm will be answered if this therapy is tested in the context of a RCT which is urgently needed. We discourage further publication of case series or single case reports on thrombolysis for CVDST, as they are unlikely to add more to our knowledge about the effect of this therapy. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are very grateful to Professor Peter Sandercock for advice during the preparation of the review, to Mrs Hazel Fraser and Mrs Brenda Thomas for help in planning the literature search and finding papers, and to all the Cochrane Stroke Group for its continuous endeavour in supporting reviewers.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>All reviewers contributed to the conception and design of this review. Dr Ciccone wrote the first draft of the review which was then checked, commented on and discussed by all other reviewers. All authors contributed to the final version of this review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-14 10:43:00 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasay-2001" NAME="Wasay 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasay M, Bakshi R, Kojan S, Bobustuc G, Dubey N, Unwin DH</AU>
<TI>Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis</TI>
<SO>Stroke</SO>
<YR>2001</YR>
<VL>32</VL>
<NO>10</NO>
<PG>2310-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-14 10:43:00 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-14 10:43:00 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Allroggen-2000" MODIFIED="2008-10-08 16:02:57 +0100" MODIFIED_BY="Hazel Fraser" NAME="Allroggen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Allroggen H, Abbott RJ</AU>
<TI>Cerebral venous sinus thrombosis</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2000</YR>
<VL>76</VL>
<PG>12-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aoki-1997" MODIFIED="2008-10-08 16:02:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Aoki 1997" TYPE="JOURNAL_ARTICLE">
<AU>Aoki N, Uchinuno H, Tanikawa T, Kagawa M, Takakura K</AU>
<TI>Superior sagittal sinus thrombosis treated with combined local thrombolytic and systemic anticoagulation therapy</TI>
<SO>Acta Neurochirurgica</SO>
<YR>1997</YR>
<VL>139</VL>
<PG>332-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnwell-1991" MODIFIED="2008-10-08 16:03:01 +0100" MODIFIED_BY="Hazel Fraser" NAME="Barnwell 1991" TYPE="JOURNAL_ARTICLE">
<AU>Barnwell SL, Higashida RT, Halbach VV, Dowd CF, Hieshima GB</AU>
<TI>Direct endovascular thrombolytic therapy for dural sinus thrombosis</TI>
<SO>Neurosurgery</SO>
<YR>1991</YR>
<VL>28</VL>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benamer-2000" MODIFIED="2008-10-08 16:03:03 +0100" MODIFIED_BY="Hazel Fraser" NAME="Benamer 2000" TYPE="JOURNAL_ARTICLE">
<AU>Benamer HTS, Bone I</AU>
<TI>Cerebral venous thrombosis: anticoagulants or thrombolytic therapy?</TI>
<SO>Journal of Neurology Neurosurgery &amp; Psychiatry</SO>
<YR>2000</YR>
<VL>69</VL>
<PG>427-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bousser-1985" MODIFIED="2008-10-08 16:03:05 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bousser 1985" TYPE="JOURNAL_ARTICLE">
<AU>Bousser MG, Chiras J, Bories J, Castaigne J</AU>
<TI>Cerebral venous thrombosis: a review of 38 cases</TI>
<SO>Stroke</SO>
<YR>1985</YR>
<VL>2</VL>
<PG>199-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bousser-1999" MODIFIED="2008-10-08 16:03:07 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bousser 1999" TYPE="JOURNAL_ARTICLE">
<AU>Bousser MG</AU>
<TI>Cerebral venous thrombosis: nothing, heparin, or local thrombolysis?</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>481-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Canh_x00e3_o-2003" NAME="Canhão 2003" TYPE="JOURNAL_ARTICLE">
<AU>Canhão P, Falcão F, Ferro JM</AU>
<TI>Thrombolytics for cerebral sinus thrombosis</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2003</YR>
<VL>15</VL>
<PG>159-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaves-2002" NAME="Chaves 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chaves C, Voetsch B, Loscalzo J, Caplan L, Chavali R</AU>
<TI>Extensive cerebral venous thrombosis associated with moderate hyperhomocyst(e)inemia and successfully treated with thrombolysis</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>3</NO>
<PG>214-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chow-2000" MODIFIED="2008-10-08 16:03:12 +0100" MODIFIED_BY="Hazel Fraser" NAME="Chow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Chow K, Gobin YP, Saver J, Kidwell C, Dong P, Viñuela F</AU>
<TI>Endovascular treatment of dural sinus thrombosis with rheolytic thrombectomy and intra-arterial thrombolysis</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>3</VL>
<PG>1420-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crassard-2003" MODIFIED="2008-10-14 10:11:05 +0100" MODIFIED_BY="Hazel Fraser" NAME="Crassard 2003" TYPE="JOURNAL_ARTICLE">
<AU>Crassard I, Canhão P, Ferro JM, Bousser MG, Barinagarrementeria F, Stam J</AU>
<TI>Neurological worsening in the acute phase of cerebral venous thrombosis in ISCVT (International Study on Cerebral Venous Thrombosis)</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2003</YR>
<VL>16 Suppl 4</VL>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Asis-2002" NAME="De Asis 2002" TYPE="JOURNAL_ARTICLE">
<AU>De Asis Bravo F, Delgado F, Cano A, Bautista MD</AU>
<TI>Cerebral venous thrombosis: treatment with local fibrinolysis plus alteplase</TI>
<SO>Radiologia</SO>
<YR>2002</YR>
<VL>44</VL>
<NO>1</NO>
<PG>23-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Bruijn-2001" MODIFIED="2008-10-14 10:12:31 +0100" MODIFIED_BY="Hazel Fraser" NAME="De Bruijn 2001" TYPE="COCHRANE_REVIEW">
<AU>De Bruijn SFTM, Deveber G, Stam J</AU>
<TI>Anticoagulants for cerebral sinus thrombosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-14 10:12:31 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-14 10:12:31 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD002005"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Del-Rio-2001" NAME="Del Rio 2001" TYPE="JOURNAL_ARTICLE">
<AU>Del Rio Camacho G, Orozco AL, Perez-Higueras A, Camino Lopez M, Al Assir I, Ruiz-Moreno M</AU>
<TI>Moyamoya disease and sagittal sinus thrombosis in a child with Down's syndrome</TI>
<SO>Pediatric Radiology</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>2</NO>
<PG>125-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Rocco-1981" MODIFIED="2008-10-08 16:03:17 +0100" MODIFIED_BY="Hazel Fraser" NAME="Di Rocco 1981" TYPE="JOURNAL_ARTICLE">
<AU>Di Rocco C, Iannelli A, Leone G, Moschini M, Valori VM</AU>
<TI>Heparin-urokinase treatment in aseptic dural sinus thrombosis</TI>
<SO>Archives of Neurology</SO>
<YR>1981</YR>
<VL>38</VL>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferro-2003" MODIFIED="2008-10-14 10:39:34 +0100" MODIFIED_BY="Hazel Fraser" NAME="Ferro 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ferro JM, Stam J, Bousser MG, Barinagarrementeria F, Canhão P, ISCVT Collaborators</AU>
<TI>The long-term prognosis of cerebral vein and dural sinus thrombosis: ISCVT results</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2003</YR>
<VL>16 Suppl 4</VL>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frey-1999" MODIFIED="2008-10-08 16:03:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="Frey 1999" TYPE="JOURNAL_ARTICLE">
<AU>Frey JL, Muro GJ, McDougall CG, Dean BL, Jahnke HK</AU>
<TI>Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>489-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Funabiki-2002" NAME="Funabiki 2002" TYPE="JOURNAL_ARTICLE">
<AU>Funabiki Y, Fujii H, Fujitake J, Takasu K, Nishimura K, Hayakawa K, Tatsuoka Y</AU>
<TI>Four cases of cerebral venous sinus thrombosis</TI>
<SO>European Neurology</SO>
<YR>2002</YR>
<VL>48</VL>
<NO>4</NO>
<PG>228-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higashida-1989" MODIFIED="2008-10-08 16:03:21 +0100" MODIFIED_BY="Hazel Fraser" NAME="Higashida 1989" TYPE="JOURNAL_ARTICLE">
<AU>Higashida RT, Helmer E, Halbach VV, Hieshima GB</AU>
<TI>Direct thrombolytic therapy for superior sagittal sinus thrombosis</TI>
<SO>American Journal of Neuroradiology</SO>
<YR>1989</YR>
<VL>10</VL>
<PG>S4-S6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holder-1997" MODIFIED="2008-10-08 16:03:25 +0100" MODIFIED_BY="Hazel Fraser" NAME="Holder 1997" TYPE="JOURNAL_ARTICLE">
<AU>Holder CA, Bell DA, Lundell AL, Ulmer JL</AU>
<TI>Isolated straight sinus and deep cerebral venous thrombosis: successful treatment with local infusion of urokinase. Case report</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1997</YR>
<VL>86</VL>
<PG>704-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horowitz-1995" MODIFIED="2008-10-08 16:03:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="Horowitz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Horowitz M, Purdy P, Unwin H, Carstens G, Greenlee R, Hise J, Kopitnik T, Batjer H, Rollins N, Samson D</AU>
<TI>Treatment of dural sinus thrombosis using selective catheterization and urokinase</TI>
<SO>Annals of Neurology</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>58-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huh-2002" NAME="Huh 2002" TYPE="JOURNAL_ARTICLE">
<AU>Huh PW, Cho KS, Yoo DS, Kim JK, Kim DS, Kang JK</AU>
<TI>Deep cerebral venous thrombosis</TI>
<SO>Acta Neurochirurgica</SO>
<YR>2002</YR>
<VL>144</VL>
<NO>1</NO>
<PG>103-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ISCVT-2003" NAME="ISCVT 2003" TYPE="OTHER">
<TI>International Study on Cerebral Vein and Dural Thrombosis (ISCVT)</TI>
<SO>www.iscvt.com</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kao-2002" NAME="Kao 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kao A, Dlugos D, Hunter JV, Mamula P, Thorarensen O</AU>
<TI>Anticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in children</TI>
<SO>Journal of Child Neurology</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>7</NO>
<PG>479-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kermode-1995" MODIFIED="2008-10-14 10:40:15 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kermode 1995" TYPE="JOURNAL_ARTICLE">
<AU>Kermode AG, Ives F, Taylor B, Davis SJ, Carroll WM</AU>
<TI>Progressive dural venous sinus thrombosis treated with local streptokinase infusion</TI>
<SO>Journal of Neurology Neurosurgery &amp; Psychiatry</SO>
<YR>1995</YR>
<VL>58</VL>
<PG>107-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-1997" MODIFIED="2008-10-08 16:03:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="Kim 1997" TYPE="JOURNAL_ARTICLE">
<AU>Kim S, Suh J</AU>
<TI>Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase</TI>
<SO>American Journal of Neuroradiology</SO>
<YR>1997</YR>
<VL>18</VL>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ming-2002" NAME="Ming 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ming S, Qi Z, Wang L, Zhu K</AU>
<TI>Deep cerebral venous thrombosis in adults</TI>
<SO>Chinese Medical Journal</SO>
<YR>2002</YR>
<VL>115</VL>
<NO>3</NO>
<PG>395-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Duenas-2002" MODIFIED="2008-10-14 10:41:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="Perez-Duenas 2002" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Duenas B, Cambra-Lasaosa FJ, Noguera-Julian A, Palomeque-Rico A, Toll-Costa T, Campistol J, et al</AU>
<TI>Cerebral venous thrombosis in a girl carrier of the prothrombin gene mutation 20210G--&gt;A treated by local fibrinolysis of the superior sagittal sinus</TI>
<SO>Revista de Neurologia</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>10</NO>
<PG>913-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Persson-1990" MODIFIED="2008-10-08 16:03:36 +0100" MODIFIED_BY="Hazel Fraser" NAME="Persson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Persson L, Lilja A</AU>
<TI>Extensive dural sinus thrombosis treated by surgical removal and local streptokinase infusion</TI>
<SO>Neurosurgery</SO>
<YR>1990</YR>
<VL>26</VL>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ra-2001" NAME="Ra 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ra CS, Lui CC, Liang CL, Chen HJ, Kuo YL, Chen WF</AU>
<TI>Superior sagittal sinus thrombosis induced by thyrotoxicosis. Case report</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2001</YR>
<VL>94</VL>
<NO>1</NO>
<PG>130-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rael-1997" MODIFIED="2008-10-08 16:03:41 +0100" MODIFIED_BY="Hazel Fraser" NAME="Rael 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rael JR, Orrison WW Jr, Baldwin N, Sell J</AU>
<TI>Direct thrombolysis of superior sagittal sinus thrombosis with coexisting intracranial hemorrhage</TI>
<SO>American Journal of Neuroradiology</SO>
<YR>1997</YR>
<VL>18</VL>
<PG>1238-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Renowden-1997" MODIFIED="2008-10-08 16:03:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="Renowden 1997" TYPE="JOURNAL_ARTICLE">
<AU>Renowden SA, Oxbury J, Molyneux AJ</AU>
<TI>Case report: venous sinus thrombosis: the use of thrombolysis</TI>
<SO>Clinical Radiology</SO>
<YR>1997</YR>
<VL>52</VL>
<PG>396-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1994" MODIFIED="2008-10-14 10:42:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="Smith 1994" TYPE="JOURNAL_ARTICLE">
<AU>Smith T, Higashida R, Barnwell S</AU>
<TI>Treatment of dural sinus thrombosis by urokinase infusion</TI>
<SO>American Journal of Neuroradiology</SO>
<YR>1994</YR>
<VL>15</VL>
<PG>801-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1997" MODIFIED="2008-10-08 16:03:48 +0100" MODIFIED_BY="Hazel Fraser" NAME="Smith 1997" TYPE="JOURNAL_ARTICLE">
<AU>Smith AG, Cornblath WT, Deveikis JP</AU>
<TI>Local thrombolytic therapy in deep cerebral venous thrombosis</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<PG>1613-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soleau-2003" MODIFIED="2008-10-14 10:42:37 +0100" MODIFIED_BY="Hazel Fraser" NAME="Soleau 2003" TYPE="JOURNAL_ARTICLE">
<AU>Soleau SW, Schmidt R, Stevens S, Osborn A, MacDonald JD, Findlay JM, et al</AU>
<TI>Extensive experience with dural sinus thrombosis</TI>
<SO>Neurosurgery</SO>
<YR>2003</YR>
<VL>52</VL>
<NO>3</NO>
<PG>534-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stam-2003" MODIFIED="2008-10-14 10:43:00 +0100" MODIFIED_BY="Hazel Fraser" NAME="Stam 2003" TYPE="COCHRANE_REVIEW">
<AU>Stam J, de Bruijn SFTM, DeVeber G</AU>
<TI>Anticoagulation for cerebral sinus thrombosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-14 10:43:00 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2008-10-14 10:43:00 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD002005"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strzyzewska-2002" NAME="Strzyzewska 2002" TYPE="JOURNAL_ARTICLE">
<AU>Strzyzewska-Lubos L, Wajgt A, Wolwender K</AU>
<TI>Cerebral venous thrombosis: a young woman case study</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>5</NO>
<PG>993-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tarani-2002" NAME="Tarani 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tarani L, Iacobini M, De Stefano V, Smacchia MP, Tozzi MC, Raguso G, Bruni L</AU>
<TI>Recombinant plasminogen activator therapy for cerebral vein thrombosis in a child carrier of prothrombin gene mutation</TI>
<SO>Journal of Pediatric Hematology Oncology</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>9</NO>
<PG>769-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2002" NAME="Yang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Yang YH, Liu CK, Shih MC, Chou MS</AU>
<TI>Fibrin-nonspecific agents in the direct thrombolytic treatment of venous sinus thrombosis</TI>
<SO>Quarterly Journal of Medicine</SO>
<YR>2002</YR>
<VL>95</VL>
<NO>11</NO>
<PG>763-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-08 16:02:03 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-10-08 16:02:03 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-10-08 16:02:03 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wasay-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-08 16:02:03 +0100" MODIFIED_BY="Hazel Fraser">
<P>Non-randomised retrospective comparison of local urokinase (20 cases) versus systemic heparin (20 cases) for superior sagittal sinus thrombosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-08 15:59:47 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2008-10-08 15:59:25 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-10-08 15:59:22 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE/CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-08 15:59:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>MEDLINE (Ovid)</P>
<P>1. "intracranial embolism and thrombosis"/<BR/>2. intracranial thrombosis/<BR/>3. exp sinus thrombosis, intracranial/<BR/>4. intracranial embolism/<BR/>5. cerebral veins/ or cavernous sinus/ or cranial sinuses/ or exp dura mater/<BR/>6. venous thrombosis/ or thrombosis/ or thromboembolism/<BR/>7. 5 and 6<BR/>8. ((cerebral vein or cerebral venous or sinus) adj5 thrombo$).tw.<BR/>9. (CVDST or CVT).tw.<BR/>10. 1 or 2 or 3 or 4 or 7 or 8 or 9<BR/>11. Thrombolytic therapy/<BR/>12. Fibrinolysis/<BR/>13. exp plasminogen activators/<BR/>14. Fibrinolytic agents/ or Plasmin/ or Plasminogen/<BR/>15. (thromboly$ or fibrinoly$ or clot lysis).tw.<BR/>16. (plasminogen or plasmin or tPA or t-PA or rtPA or rt-PA).tw.<BR/>17. (anistreplase or streptodornase or streptokinase or urokinase or pro?urokinase or rpro?uk or lumbrokinase or duteplase or lanoteplase or pamiteplase or reteplase or saruplase or staphylokinase or streptase or alteplase or tenecteplase or TNK).tw.<BR/>18. or/11-17<BR/>19. 10 and 18<BR/>20. limit 19 to human</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-10-08 15:59:47 +0100" MODIFIED_BY="Hazel Fraser" NO="2">
<TITLE MODIFIED="2008-10-08 15:59:33 +0100" MODIFIED_BY="Hazel Fraser">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-08 15:59:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>EMBASE (Ovid)</P>
<P>1. exp cerebral sinus thrombosis/<BR/>2. exp occlusive cerebrovascular disease/<BR/>3. brain embolism/<BR/>4. brain vein/ or cavernous sinus/ or dura mater/ or cranial sinus/<BR/>5. vein thrombosis/ or thrombosis/ or thromboembolism/<BR/>6. 4 and 5<BR/>7. ((cerebral vein or cerebral venous or sinus) adj5 thrombo$).tw.<BR/>8. (CVDST or CVT).tw.<BR/>9. 1 or 2 or 3 or 6 or 7 or 8<BR/>10. fibrinolytic therapy/<BR/>11. fibrinolysis/<BR/>12. blood clot lysis/<BR/>13. fibrinolytic agent/<BR/>14. plasmin/ or plasminogen/ or exp plasminogen activator/<BR/>15. exp thromboembolism/dt<BR/>16. recanalization/ or recanali#ation.tw.<BR/>17. (thromboly$ or fibrinoly$ or clot lysis).tw.<BR/>18. (plasminogen or plasmin or tpa or t-pa or rtpa or rt-pa).tw.<BR/>19. (anistreplase or streptodornase or streptokinase or urokinase or pro?urokinase or rpro?uk or lumbrokinase or duteplase or lanoteplase or pamiteplase or reteplase or saruplase or staphylokinase or streptase or alteplase or tenecteplase or TNK).tw.<BR/>20. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19<BR/>21. 9 and 20<BR/>22. limit 21 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>